These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36115922)

  • 61. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
    McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
    Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
    Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
    [TBL] [Abstract][Full Text] [Related]  

  • 63. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.
    Schelch K; Wagner C; Hager S; Pirker C; Siess K; Lang E; Lin R; Kirschner MB; Mohr T; Brcic L; Marian B; Holzmann K; Grasl-Kraupp B; Krupitza G; Laszlo V; Klikovits T; Dome B; Hegedus B; Garay T; Reid G; van Zandwijk N; Klepetko W; Berger W; Grusch M; Hoda MA
    Carcinogenesis; 2018 Apr; 39(4):534-545. PubMed ID: 29635378
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Systemic Treatment of Malignant Pleural Mesothelioma].
    Nakano T
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
    Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
    Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impact on survival of nuclear atypia in epithelioid malignant mesothelioma.
    Mlika M; Limam M; Benzarti A; Mezni F
    Adv Respir Med; 2019; 87(2):90-95. PubMed ID: 31038719
    [TBL] [Abstract][Full Text] [Related]  

  • 67. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
    Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation.
    Klebanov N; Reddy BY; Husain S; Silvers DN; Grossman ME; Tsao H
    Am J Dermatopathol; 2018 May; 40(5):378-382. PubMed ID: 29059099
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
    Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
    Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
    Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
    Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
    Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
    J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
    Nowak AK; Francis RJ; Phillips MJ; Millward MJ; van der Schaaf AA; Boucek J; Musk AW; McCoy MJ; Segal A; Robins P; Byrne MJ
    Clin Cancer Res; 2010 Apr; 16(8):2409-17. PubMed ID: 20371686
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Histopathological typing in diffuse malignant epithelioid mesothelioma: implication for prognosis and molecular basis.
    Forest F; Laville D; Habougit C; Corbasson M; Bayle-Bleuez S; Tissot C; Fournel P; Tiffet O; Péoc'h M
    Pathology; 2021 Oct; 53(6):728-734. PubMed ID: 33965253
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
    Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
    Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
    Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
    J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CD74: a new prognostic factor for patients with malignant pleural mesothelioma.
    Otterstrom C; Soltermann A; Opitz I; Felley-Bosco E; Weder W; Stahel RA; Triponez F; Robert JH; Serre-Beinier V
    Br J Cancer; 2014 Apr; 110(8):2040-6. PubMed ID: 24594996
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Accuracy of pleural biopsy for the diagnosis of histologic subtype of malignant pleural mesothelioma: Necropsy-based study of 134 cases.
    Barbieri PG; Consonni D; Schneider M
    Tumori; 2022 Feb; 108(1):26-32. PubMed ID: 33719756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.